Literature DB >> 30927075

Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model.

Lijia Chang1, Kai Zhang1, Yaoyu Pu1, Youge Qu1, Si-Ming Wang1, Zhongwei Xiong1, Yukihiko Shirayama1,2, Kenji Hashimoto3.   

Abstract

It is reported that dopamine D1 receptors in the medial prefrontal cortex play a role in the antidepressant actions of (R,S)-ketamine. However, its role in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, is unknown. In the locomotion test, tail suspension test, forced swimming test and 1% sucrose preference test, pretreatment with dopamine D1 receptor antagonist SCH-23390 did not block the antidepressant effects of (R)-ketamine in the susceptible mice after chronic social defeat stress. These findings suggest that dopamine D1 receptors may not play a major role in the antidepressant actions of (R)-ketamine.

Entities:  

Keywords:  (R)-ketamine; Antidepressant; Dopamine D1 receptor; Social defeat stress

Year:  2019        PMID: 30927075     DOI: 10.1007/s00406-019-01012-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  23 in total

Review 1.  An update on ketamine and its two enantiomers as rapid-acting antidepressants.

Authors:  Kai Zhang; Kenji Hashimoto
Journal:  Expert Rev Neurother       Date:  2018-12-04       Impact factor: 4.618

2.  Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity.

Authors:  K Hashimoto
Journal:  Psychol Med       Date:  2016-06-10       Impact factor: 7.723

3.  What Are the Causes for Discrepancies of Antidepressant Actions of (2R,6R)-Hydroxynorketamine?

Authors:  Kenji Hashimoto; Yukihiko Shirayama
Journal:  Biol Psychiatry       Date:  2017-12-27       Impact factor: 13.382

4.  R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.

Authors:  Ji-Chun Zhang; Su-Xia Li; Kenji Hashimoto
Journal:  Pharmacol Biochem Behav       Date:  2013-12-03       Impact factor: 3.533

5.  Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.

Authors:  Kenichi Fukumoto; Hidetoh Toki; Michihiko Iijima; Takashi Hashihayata; Jun-Ichi Yamaguchi; Kenji Hashimoto; Shigeyuki Chaki
Journal:  J Pharmacol Exp Ther       Date:  2017-01-23       Impact factor: 4.030

6.  Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine.

Authors:  Chun Yang; Mei Han; Ji-Chun Zhang; Qian Ren; Kenji Hashimoto
Journal:  Psychiatry Res       Date:  2016-03-24       Impact factor: 3.222

7.  Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys.

Authors:  Kenji Hashimoto; Takeharu Kakiuchi; Hiroyuki Ohba; Shingo Nishiyama; Hideo Tsukada
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-18       Impact factor: 5.270

8.  Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model.

Authors:  Chun Yang; Youge Qu; Yuko Fujita; Qian Ren; Min Ma; Chao Dong; Kenji Hashimoto
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

9.  Role of Inflammatory Bone Markers in the Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.

Authors:  Kai Zhang; Min Ma; Chao Dong; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2018-11-01       Impact factor: 5.176

10.  No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model.

Authors:  Lijia Chang; Hidetoh Toki; Youge Qu; Yuko Fujita; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

View more
  5 in total

1.  Brain-derived neurotrophic factor-TrkB signaling and the mechanism of antidepressant activity by ketamine in mood disorders.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-03       Impact factor: 5.270

Review 2.  Can I Get a Witness? Using Vicarious Defeat Stress to Study Mood-Related Illnesses in Traditionally Understudied Populations.

Authors:  Brandon L Warren; Michelle S Mazei-Robison; Alfred J Robison; Sergio D Iñiguez
Journal:  Biol Psychiatry       Date:  2020-02-18       Impact factor: 13.382

Review 3.  Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.

Authors:  Chun Yang; Jianjun Yang; Ailin Luo; Kenji Hashimoto
Journal:  Transl Psychiatry       Date:  2019-11-07       Impact factor: 6.222

4.  (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism.

Authors:  Yukio Ago; Wataru Tanabe; Momoko Higuchi; Shinji Tsukada; Tatsunori Tanaka; Takumi Yamaguchi; Hisato Igarashi; Rei Yokoyama; Kaoru Seiriki; Atsushi Kasai; Takanobu Nakazawa; Shinsaku Nakagawa; Kenji Hashimoto; Hitoshi Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2019-10-01       Impact factor: 5.176

5.  Ketamine: A tale of two enantiomers.

Authors:  Luke A Jelen; Allan H Young; James M Stone
Journal:  J Psychopharmacol       Date:  2020-11-06       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.